BTG2 and Mobius syndrome: Indeed, the favorable toxicity profile and the potent anti-neoplastic effects observed in mice treated with MEN1611 suggest that this PI3K inhibitor may be suitable alone or in combination with other targeted therapies for the treatment of the cohort of patients with Shh-type MBs and with down-regulation of the Btg2 gene.